Neuroendocrine Carcinoma Market Report and Forecast (2025-2034)
Description
The neuroendocrine carcinoma market size was valued at USD 2.44 Billion in 2024 , driven by the rising prevalence of personalised medicine across the major markets. The market is expected to grow at a CAGR of 10.03% during the forecast period of 2025-2034, with the values likely to reach USD 6.35 Billion by 2034 .
Neuroendocrine Carcinoma: Introduction
Neuroendocrine carcinoma, also referred to as neuroendocrine tumour or neoplasm, initiates in specialized cells of the neuroendocrine system. These cells are present throughout the body and possess the traits of nerve cells as well as hormone producing endocrine cells. This tumour can affect any part of the body, including lungs, pancreas, and the GI (gastrointestinal) tract. Symptoms may vary depending upon the tumor location.
Neuroendocrine Carcinoma Market Analysis
As neuroendocrine carcinoma affects the hormone cells of the body, the repercussions range from skin rashes to diarrhoea to low or high blood pressure. In such cases, somatostatin analogues like octreotide and lanreotide are used. Chemotherapy, targeted therapy, peptide receptor radionuclide therapy are other non-pharmacological interventions used to treat the condition and aid in catering to the rising neuroendocrine carcinoma market demand.
With a specific focus on treating liver NET, radioembolization is being applied to slow down the tumour growth and shrink by directly offering radiation to the liver. This is done with the help of small radioactive particles, lodged inside the tumour to inhibit blood flow and emit radiation, damaging the cancer cells.
The neuroendocrine carcinoma market growth is driven by the increasing collaborations in prominent companies to expand their product portfolio and offer improved treatment alternatives to patients. In October 2023, Eli Lilly and Company acquired Point Biopharma Global to develop radioligand therapy for treating gastroenteropancreatic neuroendocrine tumours (GEP-NETs). The acquisition costed around USD 1.4 billion, which is an indicator that the market is experiencing hefty investments to foster innovation.
Neuroendocrine Carcinoma Market Segmentation
“Neuroendocrine Carcinoma Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:
Market Breakup by Treatment Type
The United States has dominated the neuroendocrine carcinoma market share, driven by the rising collaborations between research and academic institutions. In June 2023, Stanford University’s Innovative Medicines Accelerator (IMA) and Intonation Research Laboratories (Intonation) collaborated to develop treatments for cancerous neuroendocrine tumors. With a robust healthcare infrastructure, the region is expected to lead the market in the forecast period as well.
Europe is another major market with numerous well-equipped healthcare and research infrastructure to foster new therapies for neuroendocrine carcinoma treatment. Major collaborations amongst healthcare companies are also contributing to the market value.
With continuously improving medical ecosystem, the Asia Pacific region, particularly Japan, is anticipated to experience maximum neuroendocrine carcinoma market growth. To leverage the academic talent and other resources, countries with emerging economies like India, and South Korea are also witnessing an influx of foreign capital. Such investments may boost the market growth significantly in the forecast period.
Neuroendocrine Carcinoma Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
*Please Note:* The report will take 5 business days to complete, after order confirmation.
Neuroendocrine Carcinoma: Introduction
Neuroendocrine carcinoma, also referred to as neuroendocrine tumour or neoplasm, initiates in specialized cells of the neuroendocrine system. These cells are present throughout the body and possess the traits of nerve cells as well as hormone producing endocrine cells. This tumour can affect any part of the body, including lungs, pancreas, and the GI (gastrointestinal) tract. Symptoms may vary depending upon the tumor location.
Neuroendocrine Carcinoma Market Analysis
As neuroendocrine carcinoma affects the hormone cells of the body, the repercussions range from skin rashes to diarrhoea to low or high blood pressure. In such cases, somatostatin analogues like octreotide and lanreotide are used. Chemotherapy, targeted therapy, peptide receptor radionuclide therapy are other non-pharmacological interventions used to treat the condition and aid in catering to the rising neuroendocrine carcinoma market demand.
With a specific focus on treating liver NET, radioembolization is being applied to slow down the tumour growth and shrink by directly offering radiation to the liver. This is done with the help of small radioactive particles, lodged inside the tumour to inhibit blood flow and emit radiation, damaging the cancer cells.
The neuroendocrine carcinoma market growth is driven by the increasing collaborations in prominent companies to expand their product portfolio and offer improved treatment alternatives to patients. In October 2023, Eli Lilly and Company acquired Point Biopharma Global to develop radioligand therapy for treating gastroenteropancreatic neuroendocrine tumours (GEP-NETs). The acquisition costed around USD 1.4 billion, which is an indicator that the market is experiencing hefty investments to foster innovation.
Neuroendocrine Carcinoma Market Segmentation
“Neuroendocrine Carcinoma Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:
Market Breakup by Treatment Type
- Somatostatin Analogs (SSAs)
- Targeted Therapy
- Chemotherapy
- Others
- Lungs
- Pancreas
- Gastrointestinal
- Others
- Hospitals
- Clinics
- Others
- United States
- United Kingdom
- Germany
- France
- Italy
- Spain
- Japan
The United States has dominated the neuroendocrine carcinoma market share, driven by the rising collaborations between research and academic institutions. In June 2023, Stanford University’s Innovative Medicines Accelerator (IMA) and Intonation Research Laboratories (Intonation) collaborated to develop treatments for cancerous neuroendocrine tumors. With a robust healthcare infrastructure, the region is expected to lead the market in the forecast period as well.
Europe is another major market with numerous well-equipped healthcare and research infrastructure to foster new therapies for neuroendocrine carcinoma treatment. Major collaborations amongst healthcare companies are also contributing to the market value.
With continuously improving medical ecosystem, the Asia Pacific region, particularly Japan, is anticipated to experience maximum neuroendocrine carcinoma market growth. To leverage the academic talent and other resources, countries with emerging economies like India, and South Korea are also witnessing an influx of foreign capital. Such investments may boost the market growth significantly in the forecast period.
Neuroendocrine Carcinoma Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb
- Eli Lilly & Company
- F. Hoffmann-La Roche Ltd.
- Ipsen
- Baxter
- Novartis AG
- Pfizer Inc.
- Lantheus Holdings, Inc.
- Tarveda Therapeutics
- AVEO Pharmaceuticals, Inc.
- Advanced Accelerator Applications
- BioSynthema Inc.
- Merck Sharp & Dohme Corp.
- Bionano Genomics
*Please Note:* The report will take 5 business days to complete, after order confirmation.
Table of Contents
350 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Neuroendocrine Carcinoma Overview
- 3.1 Guidelines and Stages
- 3.2 Pathophysiology
- 3.3 Screening and Diagnosis
- 3.4 Treatment Pathway
- 4 Patient Profile
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Neuroendocrine Carcinoma Epidemiology Analysis – 7MM
- 5.1 7MM Epidemiology Scenario Overview (2018-2034)
- 5.2 United States Neuroendocrine Carcinoma Epidemiology Forecast (2018-2034)
- 5.3 EU-4 and United Kingdom Neuroendocrine Carcinoma Epidemiology Forecast (2018-2034)
- 5.3.1 Germany Neuroendocrine Carcinoma Epidemiology Forecast (2018-2034)
- 5.3.2 France Neuroendocrine Carcinoma Epidemiology Forecast (2018-2034)
- 5.3.3 Italy Neuroendocrine Carcinoma Epidemiology Forecast (2018-2034)
- 5.3.4 Spain Neuroendocrine Carcinoma Epidemiology Forecast (2018-2034)
- 5.3.5 United Kingdom Neuroendocrine Carcinoma Epidemiology Forecast (2018-2034)
- 5.4 Japan Neuroendocrine Carcinoma Epidemiology Forecast (2018-2034)
- 6 Neuroendocrine Carcinoma Market Overview – 7MM
- 6.1 Neuroendocrine Carcinoma Market Historical Value (2018-2024)
- 6.2 Neuroendocrine Carcinoma Market Forecast Value (2025-2034)
- 7 Neuroendocrine Carcinoma Market Landscape – 7MM
- 7.1 Neuroendocrine Carcinoma Developers Landscape
- 7.1.1 Analysis by Year of Establishment
- 7.1.2 Analysis by Company Size
- 7.1.3 Analysis by Region
- 7.2 Neuroendocrine Carcinoma Product Landscape
- 7.2.1 Analysis by Products
- 7.2.2 Analysis by Indications
- 7.2.3 Analysis by Route of Administration
- 8 Neuroendocrine Carcinoma Challenges and Unmet Needs
- 8.1 Treatment Pathway Challenges
- 8.2 Compliance and Drop-Out Analysis
- 8.3 Awareness and Prevention Gaps
- 9 Cost of Treatment
- 10 Neuroendocrine Carcinoma Market Dynamics
- 10.1 Market Drivers and Constraints
- 10.2 SWOT Analysis
- 10.3 Porter’s Five Forces Model
- 10.4 Key Demand Indicators
- 10.5 Key Price Indicators
- 10.6 Industry Events, Initiatives, and Trends
- 10.7 Value Chain Analysis
- 11 Neuroendocrine Carcinoma Market Segmentation – 7MM
- 11.1 Neuroendocrine Carcinoma Market by Treatment Type
- 11.1.1 Market Overview
- 11.1.2 Somatostatin Analogs (SSAs)
- 11.1.3 Targeted Therapy
- 11.1.4 Chemotherapy
- 11.1.5 Others
- 11.2 Neuroendocrine Carcinoma Market by Indication
- 11.2.1 Market Overview
- 11.2.2 Lungs
- 11.2.3 Pancreas
- 11.2.4 Gastrointestinal
- 11.2.5 Others
- 11.3 Neuroendocrine Carcinoma Market by End User
- 11.3.1 Market Overview
- 11.3.2 Hospitals
- 11.3.3 Clinics
- 11.3.4 Others
- 11.4 Neuroendocrine Carcinoma Market by Region
- 11.4.1 Market Overview
- 11.4.2 United States
- 11.4.3 EU-4 and the United Kingdom
- 11.4.3.1 Germany
- 11.4.3.2 France
- 11.4.3.3 Italy
- 11.4.3.4 Spain
- 11.4.3.5 United Kingdom
- 11.4.4 Japan
- 12 United States Neuroendocrine Carcinoma Market
- 12.1 Neuroendocrine Carcinoma Market Historical Value (2018-2024)
- 12.2 Neuroendocrine Carcinoma Market Forecast Value (2025-2034)
- 12.2.1 Neuroendocrine Carcinoma Market by Indication
- 12.2.2 Neuroendocrine Carcinoma Market by Treatment Type
- 13 EU-4 and United Kingdom Neuroendocrine Carcinoma Market
- 13.1 Neuroendocrine Carcinoma Market Historical Value (2018-2024)
- 13.2 Neuroendocrine Carcinoma Market Forecast Value (2025-2034)
- 13.3 Germany Neuroendocrine Carcinoma Market Overview
- 13.3.1 Neuroendocrine Carcinoma Market by Indication
- 13.3.2 Neuroendocrine Carcinoma Market by Treatment Type
- 13.4 France Neuroendocrine Carcinoma Market Overview
- 13.4.1 Neuroendocrine Carcinoma Market by Indication
- 13.4.2 Neuroendocrine Carcinoma Market by Treatment Type
- 13.5 Italy Neuroendocrine Carcinoma Market Overview
- 13.5.1 Neuroendocrine Carcinoma Market by Indication
- 13.5.2 Neuroendocrine Carcinoma Market by Treatment Type
- 13.6 Spain Neuroendocrine Carcinoma Market Overview
- 13.6.1 Neuroendocrine Carcinoma Market by Indication
- 13.6.2 Neuroendocrine Carcinoma Market by Treatment Type
- 13.7 United Kingdom Neuroendocrine Carcinoma Market Overview
- 13.7.1 Neuroendocrine Carcinoma Market by Indication
- 13.7.2 Neuroendocrine Carcinoma Market by Treatment Type
- 14 Japan Neuroendocrine Carcinoma Market
- 14.1 Neuroendocrine Carcinoma Market Historical Value (2018-2024)
- 14.2 Neuroendocrine Carcinoma Market Forecast Value (2025-2034)
- 14.3 Neuroendocrine Carcinoma Market by Indication
- 14.4 Neuroendocrine Carcinoma Market by Treatment Type
- 15 Patent Analysis
- 15.1 Analysis by Type of Patent
- 15.2 Analysis by Publication year
- 15.3 Analysis by Issuing Authority
- 15.4 Analysis by Patent Age
- 15.5 Analysis by CPC Analysis
- 15.6 Analysis by Patent Valuation
- 15.7 Analysis by Key Players
- 16 Grants Analysis
- 16.1 Analysis by year
- 16.2 Analysis by Amount Awarded
- 16.3 Analysis by Issuing Authority
- 16.4 Analysis by Grant Application
- 16.5 Analysis by Funding Institute
- 16.6 Analysis by NIH Departments
- 16.7 Analysis by Recipient Organization
- 17 Clinical Trials Analysis
- 17.1 Analysis by Trial Registration Year
- 17.2 Analysis by Trial Status
- 17.3 Analysis by Trial Phase
- 17.4 Analysis by Therapeutic Area
- 17.5 Analysis by Geography
- 18 Funding Analysis
- 18.1 Analysis by Funding Instances
- 18.2 Analysis by Type of Funding
- 18.3 Analysis by Funding Amount
- 18.4 Analysis by Leading Players
- 18.5 Analysis by Leading Investors
- 18.6 Analysis by Geography
- 19 Partnership and Collaborations Analysis
- 19.1 Analysis by Partnership Instances
- 19.2 Analysis by Type of Partnership
- 19.3 Analysis by Leading Players
- 19.4 Analysis by Geography
- 20 Supplier Landscape
- 20.1 Boehringer Ingelheim International GmbH
- 20.1.1 Financial Analysis
- 20.1.2 Product Portfolio
- 20.1.3 Demographic Reach and Achievements
- 20.1.4 Mergers and Acquisitions
- 20.1.5 Certifications
- 20.2 Bristol-Myers Squibb
- 20.2.1 Financial Analysis
- 20.2.2 Product Portfolio
- 20.2.3 Demographic Reach and Achievements
- 20.2.4 Mergers and Acquisitions
- 20.2.5 Certifications
- 20.3 Eli Lilly & Company
- 20.3.1 Financial Analysis
- 20.3.2 Product Portfolio
- 20.3.3 Demographic Reach and Achievements
- 20.3.4 Mergers and Acquisitions
- 20.3.5 Certifications
- 20.4 F. Hoffmann-La Roche Ltd.
- 20.4.1 Financial Analysis
- 20.4.2 Product Portfolio
- 20.4.3 Demographic Reach and Achievements
- 20.4.4 Mergers and Acquisitions
- 20.4.5 Certifications
- 20.5 Ipsen
- 20.5.1 Financial Analysis
- 20.5.2 Product Portfolio
- 20.5.3 Demographic Reach and Achievements
- 20.5.4 Mergers and Acquisitions
- 20.5.5 Certifications
- 20.6 Baxter
- 20.6.1 Financial Analysis
- 20.6.2 Product Portfolio
- 20.6.3 Demographic Reach and Achievements
- 20.6.4 Mergers and Acquisitions
- 20.6.5 Certifications
- 20.7 Novartis AG
- 20.7.1 Financial Analysis
- 20.7.2 Product Portfolio
- 20.7.3 Demographic Reach and Achievements
- 20.7.4 Mergers and Acquisitions
- 20.7.5 Certifications
- 20.8 Pfizer Inc.
- 20.8.1 Financial Analysis
- 20.8.2 Product Portfolio
- 20.8.3 Demographic Reach and Achievements
- 20.8.4 Mergers and Acquisitions
- 20.8.5 Certifications
- 20.9 Lantheus Holdings, Inc.
- 20.9.1 Financial Analysis
- 20.9.2 Product Portfolio
- 20.9.3 Demographic Reach and Achievements
- 20.9.4 Mergers and Acquisitions
- 20.9.5 Certifications
- 20.10 Tarveda Therapeutics
- 20.10.1 Financial Analysis
- 20.10.2 Product Portfolio
- 20.10.3 Demographic Reach and Achievements
- 20.10.4 Mergers and Acquisitions
- 20.10.5 Certifications
- 20.11 AVEO Pharmaceuticals, Inc.
- 20.11.1 Financial Analysis
- 20.11.2 Product Portfolio
- 20.11.3 Demographic Reach and Achievements
- 20.11.4 Mergers and Acquisitions
- 20.11.5 Certifications
- 20.12 Advanced Accelerator Applications
- 20.12.1 Financial Analysis
- 20.12.2 Product Portfolio
- 20.12.3 Demographic Reach and Achievements
- 20.12.4 Mergers and Acquisitions
- 20.12.5 Certifications
- 20.13 BioSynthema Inc.
- 20.13.1 Financial Analysis
- 20.13.2 Product Portfolio
- 20.13.3 Demographic Reach and Achievements
- 20.13.4 Mergers and Acquisitions
- 20.13.5 Certifications
- 20.14 Merck
- 20.14.1 Financial Analysis
- 20.14.2 Product Portfolio
- 20.14.3 Demographic Reach and Achievements
- 20.14.4 Mergers and Acquisitions
- 20.14.5 Certifications
- 20.15 Bionano Genomics
- 20.15.1 Financial Analysis
- 20.15.2 Product Portfolio
- 20.15.3 Demographic Reach and Achievements
- 20.15.4 Mergers and Acquisitions
- 20.15.5 Certifications
- 21 Neuroendocrine Carcinoma Market - Distribution Model (Additional Insight)
- 21.1 Overview
- 21.2 Potential Distributors
- 21.3 Key Parameters for Distribution Partner Assessment
- 22 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 23 Company Competitiveness Analysis (Additional Insight)
- 23.1 Very Small Companies
- 23.2 Small Companies
- 23.3 Mid-Sized Companies
- 23.4 Large Companies
- 23.5 Very Large Companies
- 24 Payment Methods (Additional Insight)
- 24.1 Government Funded
- 24.2 Private Insurance
- 24.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
